AbCellera Biologics (ABCL) Set to Announce Earnings on Monday

AbCellera Biologics (NASDAQ:ABCL) is anticipated to post its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect AbCellera Biologics to post earnings of ($0.1706) per share and revenue of $8.41 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 5:00 PM ET.

AbCellera Biologics (NASDAQ:ABCL) last issued its earnings results on Wednesday, August 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). The firm had revenue of $4.05 million during the quarter, compared to the consensus estimate of $7.85 million. AbCellera Biologics had a negative return on equity of 17.49% and a negative net margin of 248.83%. On average, analysts expect AbCellera Biologics to post ($0.69) EPS for the current fiscal year and ($0.82) EPS for the next fiscal year.

AbCellera Biologics Stock Performance

NASDAQ ABCL opened at $11.97 on Monday. The stock has a 50 day moving average price of $12.29 and a 200-day moving average price of $6.85. AbCellera Biologics has a one year low of $2.74 and a one year high of $15.02. The company has a market capitalization of $3.67 billion, a P/E ratio of -22.29 and a beta of 1.59.

Wall Street Analyst Weigh In

ABCL has been the subject of several analyst reports. UBS Group initiated coverage on shares of AbCellera Biologics in a research note on Monday, October 12th. They issued a “buy” rating and a $18.00 price objective for the company. JPMorgan Chase & Co. began coverage on AbCellera Biologics in a report on Tuesday, September 29th. They issued an “overweight” rating and a $17.00 price target on the stock. Cantor Fitzgerald boosted their price objective on AbCellera Biologics from $11.00 to $12.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Stifel Nicolaus upped their price objective on AbCellera Biologics from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AbCellera Biologics in a research note on Thursday, October 15th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $14.60.

About AbCellera Biologics

AbCellera Biologics Inc is a biotechnology company headquartered in Vancouver, British Columbia, that develops antibody-based medicines and provides antibody discovery services to pharmaceutical and biotechnology companies. Its platform is designed to identify therapeutic antibodies from immune cells and accelerate their progression from discovery through development.

The company combines high-throughput screening, microfluidics, single-cell analysis, automation, and artificial intelligence to evaluate large numbers of antibody candidates.